Abstract

The synthetic biology firm Ginkgo Bioworks has raised $290 million in a fifth round of funding from investors including T. Rowe Price, Viking Global Investors, and Bill Gates’s Cascade Investment t...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call